{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:17:30Z","timestamp":1758759450530,"version":"3.44.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03186-5","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T21:44:54Z","timestamp":1754948694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a pH Gradient Dissolution Condition to Predict the Behavior of Delayed Release Formulations under Fed In Vivo Condition"],"prefix":"10.1208","volume":"26","author":[{"given":"Juilee","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibhuranjan","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-0003","authenticated-orcid":false,"given":"Sajeev","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"6","key":"3186_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1211\/0022357056172","volume":"57","author":"S Klein","year":"2005","unstructured":"Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol. 2005;57(6):709\u201319.","journal-title":"J Pharm Pharmacol"},{"key":"3186_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12325-015-0206-4","volume":"32","author":"A Abinusawa","year":"2015","unstructured":"Abinusawa A, Tenjarla S. Release of 5-aminosalicylic acid (5-ASA) from Mesalamine formulations at various pH levels. Adv Ther. 2015;32:477\u201384.","journal-title":"Adv Ther"},{"issue":"18","key":"3186_CR3","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.3390\/ijms21186502","volume":"21","author":"AH Teruel","year":"2020","unstructured":"Teruel AH, Gonzalez-Alvarez I, Bermejo M, Merino V, Marcos MD, Sancenon F, Gonzalez-Alvarez M, Martinez-Ma\u00f1ez R. New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy. Int J Mol Sci. 2020;21(18):6502.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3186_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/pharmaceutics14020291","volume":"14","author":"MA Garc\u00eda","year":"2022","unstructured":"Garc\u00eda MA, Varum F, Al-Gousous J, Hofmann M, Page S, Langguth P. In vitro methodologies for evaluating colon-targeted pharmaceutical products and industry perspectives for their applications. Pharmaceutics. 2022;14(2):291.","journal-title":"Pharmaceutics"},{"issue":"11\u201312","key":"3186_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/j.1365-2036.2004.02267.x","volume":"20","author":"D Lesbros-Pantoflickova","year":"2004","unstructured":"Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(11\u201312):1253\u201369.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3186_CR6","first-page":"183","volume":"46","author":"J Fallingborg","year":"1999","unstructured":"Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999;46(3):183\u201396.","journal-title":"Dan Med Bull"},{"issue":"4","key":"3186_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/0016-5085(86)90873-5","volume":"90","author":"L Ovesen","year":"1986","unstructured":"Ovesen L, Bendtsen F, Tage-Jensen U, Pedersen NT, Gram BR, Rune SJ. Intraluminal pH in the stomach, duodenum, and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology. 1986;90(4):958\u201362.","journal-title":"Gastroenterology"},{"key":"3186_CR8","doi-asserted-by":"publisher","first-page":"106821","DOI":"10.1016\/j.ejps.2024.106821","volume":"31","author":"S Steigert","year":"2024","unstructured":"Steigert S, Brouwers J, Verbeke K, Vanuytsel T, Augustijns P. Characterization of luminal contents from the fasted human proximal colon. Eur J Pharm Sci. 2024;31:106821.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"3186_CR9","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1021\/mp100149j","volume":"7","author":"DM Mudie","year":"2010","unstructured":"Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 2010;7(5):1388\u2013405.","journal-title":"Mol Pharm"},{"key":"3186_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1208\/s12248-016-9952-8","volume":"18","author":"AY Abuhelwa","year":"2016","unstructured":"Abuhelwa AY, Foster DJ, Upton RN. A quantitative review and meta-models of the variability and factors affecting oral drug absorption\u2014part I: gastrointestinal pH. AAPS J. 2016;18:1309\u201321.","journal-title":"AAPS J"},{"issue":"112","key":"3186_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejpb.2016.11.034","volume":"1","author":"AY Abuhelwa","year":"2017","unstructured":"Abuhelwa AY, Williams DB, Upton RN, Foster DJ. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm. 2017;1(112):234\u201348.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"3186_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/pharmaceutics15020587","volume":"15","author":"A Nikam","year":"2023","unstructured":"Nikam A, Sahoo PR, Musale S, Pagar RR, Paiva-Santos AC, Giram PS. A systematic overview of Eudragit\u00ae based copolymer for smart healthcare. Pharmaceutics. 2023;15(2):587.","journal-title":"Pharmaceutics"},{"key":"3186_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1023\/A:1015937912504","volume":"5","author":"SS Ozturk","year":"1988","unstructured":"Ozturk SS, Palsson BO, Donohoe B, Dressman JB. Kinetics of release from enteric-coated tablets. Pharm Res. 1988;5:550\u201365.","journal-title":"Pharm Res"},{"key":"3186_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1208\/s12248-011-9272-y","volume":"13","author":"OM Anand","year":"2011","unstructured":"Anand OM, Yu LX, Conner DP, Davit BM. Dissolution testing for generic drugs: an FDA perspective. AAPS J. 2011;13:328\u201335.","journal-title":"AAPS J"},{"issue":"1","key":"3186_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.xphs.2017.10.019","volume":"107","author":"H Grady","year":"2018","unstructured":"Grady H, Elder D, Webster GK, Mao Y, Lin Y, Flanagan T, Mann J, Blanchard A, Cohen MJ, Lin J, Kesisoglou F. Industry\u2019s view on using quality control, biorelevant, and clinically relevant dissolution tests for pharmaceutical development, registration, and commercialization. J Pharm Sci. 2018;107(1):34\u201341.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3186_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","volume":"12","author":"S Klein","year":"2010","unstructured":"Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12(3):397\u2013406.","journal-title":"AAPS J"},{"issue":"1","key":"3186_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.xphs.2016.06.001","volume":"106","author":"R Cristofoletti","year":"2017","unstructured":"Cristofoletti R, Dressman JB. Dissolution methods to increasing discriminatory power of in vitro dissolution testing for ibuprofen free acid and its salts. J Pharm Sci. 2017Jan 1;106(1):92\u20139.","journal-title":"J Pharm Sci"},{"issue":"93","key":"3186_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejpb.2015.03.009","volume":"1","author":"C Markopoulos","year":"2015","unstructured":"Markopoulos C, Andreas CJ, Vertzoni M, Dressman J, Reppas C. In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media. Eur J Pharm Biopharm. 2015Jun;1(93):173\u201382.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"3186_CR19","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.ejpb.2013.09.009","volume":"85","author":"A Kambayashi","year":"2013","unstructured":"Kambayashi A, Blume H, Dressman J. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac. Eur J Pharm Biopharm. 2013Nov 1;85(3):1337\u201347.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3186_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejpb.2011.01.001","volume":"78","author":"F Liu","year":"2011","unstructured":"Liu F, Merchant HA, Kulkarni RP, Alkademi M, Basit AW. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products. Eur J Pharm Biopharm. 2011;78(1):151\u20137.","journal-title":"Eur J Pharm Biopharm"},{"key":"3186_CR21","doi-asserted-by":"crossref","unstructured":"Blachier F, de S\u00e1 Resende A, da Silva Foga\u00e7a Leite G, Vasques da Costa A, Lancha Junior AH. Colon epithelial cells luminal environment and physiopathological consequences: impact of nutrition and exercise. Nutrire. 2018;43:1\u20139.","DOI":"10.1186\/s41110-018-0061-6"},{"issue":"6","key":"3186_CR22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.xphs.2018.02.016","volume":"107","author":"F Karkossa","year":"2018","unstructured":"Karkossa F, Klein S. A biopredictive in vitro comparison of oral locally acting Mesalazine formulations by a novel dissolution model for assessing intraluminal drug release in individual subjects. J Pharm Sci. 2018;107(6):1680\u20139.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3186_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/ma14030555","volume":"14","author":"M Vlachou","year":"2021","unstructured":"Vlachou M, Karalis V. An in vitro\u2013in vivo simulation approach for the prediction of bioequivalence. Materials. 2021Jan 24;14(3):555.","journal-title":"Materials"},{"key":"3186_CR24","unstructured":"Guidance for Industry. Bioequivalence studies with pharmacokinetic endpoints for drug submitted under an ANDA. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2013."},{"key":"3186_CR25","unstructured":"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/dsp_SearchResults.cfm (Accessed on 08\/10\/2024 14:29 IST)"},{"issue":"2","key":"3186_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/gut.28.2.196","volume":"28","author":"B Myers","year":"1987","unstructured":"Myers B, Evans DN, Rhodes J, Evans BK, Hughes BR, Lee MG, Richens A, Richards D. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28(2):196\u2013200.","journal-title":"Gut"},{"key":"3186_CR27","unstructured":"https:\/\/onlinehelp.certara.com\/phoenix\/8.2\/topics\/ivivcobject.htm (Accessed on 08\/10\/2024 14:21 IST)"},{"key":"3186_CR28","unstructured":"https:\/\/onlinehelp.certara.com\/phoenix\/8.2\/topics\/ivivcresults.htm (Accessed on 08\/10\/2024 14:19 IST)"},{"key":"3186_CR29","unstructured":"US FDA, Guidance for Industry, extended release oral dosage forms: development, evaluation, and application of in vitro\/in vivo correlations, 1997."},{"key":"3186_CR30","doi-asserted-by":"publisher","first-page":"105844","DOI":"10.1016\/j.jddst.2024.105844","volume":"11","author":"HM Fadda","year":"2024","unstructured":"Fadda HM. Effect of postprandial gastric conditions on in vitro drug release from modified release Mesalamine formulations. J Drug Deliv Sci Technol. 2024;11:105844.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"3186_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/clpt.1987.3","volume":"41","author":"P Mojaverian","year":"1987","unstructured":"Mojaverian P, Rocci ML Jr, Conner DP, Abrams WB, Vlasses PH. Effect of food on the absorption of enteric-coated aspirin: Correlation with gastric residence time. Clin Pharmacol Ther. 1987;41(1):11\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3186_CR32","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.ejpb.2013.09.009","volume":"85","author":"A Kambayashi","year":"2013","unstructured":"Kambayashi A, Blume H, Dressman J. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac. Eur J Pharm Biopharm. 2013;85(3):1337\u201347.","journal-title":"Eur J Pharm Biopharm"},{"key":"3186_CR33","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1007\/s11095-008-9580-9","volume":"25","author":"VC Ibekwe","year":"2008","unstructured":"Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008;25:1828\u201335.","journal-title":"Pharm Res"},{"key":"3186_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13346-013-0185-4","volume":"4","author":"R Malayandi","year":"2014","unstructured":"Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res. 2014;4:187\u2013202.","journal-title":"Drug Deliv Transl Res"},{"key":"3186_CR35","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1023\/A:1018974519984","volume":"16","author":"SY Zhou","year":"1999","unstructured":"Zhou SY, Piyapolrungroj N, Pao LH, Li C, Liu G, Zimmermann E, Fleisher D. Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine. Pharm Res. 1999;16:1781\u20135.","journal-title":"Pharm Res"},{"issue":"4","key":"3186_CR36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0090-9556(24)15210-5","volume":"27","author":"SY Zhou","year":"1999","unstructured":"Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos. 1999;27(4):479\u201385.","journal-title":"Drug Metab Dispos"},{"key":"3186_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0773.1997.tb01944.x","volume":"81","author":"S Bondesen","year":"1997","unstructured":"Bondesen S. Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. Pharmacol Toxicol. 1997;81:1\u201330.","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"3186_CR38","first-page":"100024","volume":"1","author":"JA Barbosa","year":"2019","unstructured":"Barbosa JA, Abdelsadig MS, Conway BR, Merchant HA. Using zeta potential to study the ionisation behaviour of polymers employed in modified-release dosage forms and estimating their pKa. Int J Pharm: X. 2019;1(1):100024.","journal-title":"Int J Pharm: X"},{"issue":"5","key":"3186_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S1461-5347(99)00151-0","volume":"2","author":"CS Leopold","year":"1999","unstructured":"Leopold CS. Coated dosage forms for colon-specific drug delivery. Pharm Sci Technol Today. 1999;2(5):197\u2013204.","journal-title":"Pharm Sci Technol Today"},{"issue":"4","key":"3186_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1211\/0022357022935","volume":"56","author":"M Vertzoni","year":"2004","unstructured":"Vertzoni M, Fotaki N, Nicolaides E, Reppas C, Kostewicz E, Stippler E, Leuner C, Dressman J. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J Pharm Pharmacol. 2004;56(4):453\u201362.","journal-title":"J Pharm Pharmacol"},{"key":"3186_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1023\/A:1011910801212","volume":"15","author":"E Galia","year":"1998","unstructured":"Galia E, Nicolaides E, H\u00f6rter D, L\u00f6benberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15:698\u2013705.","journal-title":"Pharm Res"},{"key":"3186_CR42","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-010-0223-6","volume":"27","author":"M Vertzoni","year":"2010","unstructured":"Vertzoni M, Diakidou A, Chatzilias M, S\u00f6derlind E, Abrahamsson B, Dressman JB, Reppas C. Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility. Pharm Res. 2010;27:2187\u201396.","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"3186_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0378-5173(91)90175-N","volume":"70","author":"M Efentakis","year":"1991","unstructured":"Efentakis M, Al-Hmoud H, Buckton G, Rajan Z. The influence of surfactants on drug release from a hydrophobic matrix. Int J Pharm. 1991;70(1\u20132):153\u20138.","journal-title":"Int J Pharm"},{"issue":"4","key":"3186_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/10837450701369170","volume":"12","author":"G Heinicke","year":"2007","unstructured":"Heinicke G, Schwartz JB. The influence of surfactants and additives on drug release from a cationic Eudragit coated multiparticulate diltiazem formulation. Pharm Dev Technol. 2007;12(4):381\u20139.","journal-title":"Pharm Dev Technol"},{"issue":"23\u201324","key":"3186_CR45","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.drudis.2013.08.013","volume":"18","author":"SS Jambhekar","year":"2013","unstructured":"Jambhekar SS, Breen PJ. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov Today. 2013;18(23\u201324):1173\u201384.","journal-title":"Drug Discov Today"},{"issue":"1\u20132","key":"3186_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijpharm.2014.09.023","volume":"476","author":"R Wulff","year":"2014","unstructured":"Wulff R, Leopold CS. Coatings from blends of Eudragit\u00ae RL and L55: A novel approach in pH-controlled drug release. Int J Pharm. 2014;476(1\u20132):78\u201387.","journal-title":"Int J Pharm"},{"key":"3186_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-020-0417-8","volume":"22","author":"DM Mudie","year":"2020","unstructured":"Mudie DM, Samiei N, Marshall DJ, Amidon GE, Bergstr\u00f6m CA. Selection of in vivo predictive dissolution media using drug substance and physiological properties. AAPS J. 2020;22:1\u20133.","journal-title":"AAPS J"},{"issue":"3","key":"3186_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0939-6411(01)00134-5","volume":"51","author":"MW Rudolph","year":"2001","unstructured":"Rudolph MW, Klein S, Beckert TE, Petereit HU, Dressman JB. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001;51(3):183\u201390.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3186_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.fjps.2017.02.001","volume":"3","author":"CN Patra","year":"2017","unstructured":"Patra CN, Priya R, Swain S, Jena GK, Panigrahi KC, Ghose D. Pharmaceutical significance of Eudragit: A review. Future J Pharm Sci. 2017;3(1):33\u201345.","journal-title":"Future J Pharm Sci"},{"issue":"2","key":"3186_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0378-5173(93)90151-5","volume":"90","author":"JL Johnson","year":"1993","unstructured":"Johnson JL, Holinej J, Williams MD. Influence of ionic strength on matrix integrity and drug release from hydroxypropyl cellulose compacts. Int J Pharm. 1993;90(2):151\u20139.","journal-title":"Int J Pharm"},{"issue":"106","key":"3186_CR51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ejps.2017.06.021","volume":"30","author":"S Cascone","year":"2017","unstructured":"Cascone S. Modeling and comparison of release profiles: Effect of the dissolution method. Eur J Pharm Sci. 2017;30(106):352\u201361.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"3186_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1208\/s12249-022-02355-0","volume":"23","author":"DY Usta","year":"2022","unstructured":"Usta DY, Incecayir T. Modeling of in vitro dissolution profiles of carvedilol immediate-release tablets in different dissolution media. AAPS PharmSciTech. 2022;23(6):201.","journal-title":"AAPS PharmSciTech"},{"issue":"201","key":"3186_CR53","doi-asserted-by":"publisher","first-page":"106864","DOI":"10.1016\/j.ejps.2024.106864","volume":"1","author":"A Ruiz-Picazo","year":"2024","unstructured":"Ruiz-Picazo A, Gonzalez-Alvarez I, Bermejo M, Gonzalez-Alvarez M. New mathematical model from dynamic dissolution rate tests. Eur J Pharm Sci. 2024;1(201):106864.","journal-title":"Eur J Pharm Sci"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03186-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:05:23Z","timestamp":1758729923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03186-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3186"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03186-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"type":"electronic","value":"1530-9932"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"211"}}